
    
      This is a multi-center, double-blind, randomized parallel group study conducted in patients
      with advanced medical illness and opioid-induced constipation. Eligible patients are randomly
      assigned to receive SC doses of either MNTX, dose 1 or placebo every other day for 2 weeks.
      At Day 8, eligible patients, if allowed, could be escalated to a a higher dose of MNTX.
    
  